Vitrakvi for Adult and Pediatric Solid Tumors

February 13, 2019

Vitrakvi (larotrectinib, Bayer and Loo Oncology Inc)

Indications: treatment of adult and pediatric patients with solid tumors that:

  • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,

  • are metastatic or where surgical resection is likely to result in severe morbidity, and

  • have no satisfactory alternative treatments or that have progressed following treatment.

Dosage:

  • Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared: 100 mg orally twice daily

  • Pediatric Patients with Body Surface Area of Less Than 1.0 Meter-Squared: 100 mg/m2 orally twice daily

Contraindications: None

Click here for more prescribing information